BEIJING, Aug. 28 /Xinhua-PRNewswire-FirstCall/ -- China Medical Technologies, Inc. (the “Company”) , a leading China-based medical device company that develops, manufactures and markets advanced in- vitro diagnostic products and high intensity focused ultrasound tumor therapy system, today announced its unaudited financial results for the first quarter ended June 30, 2007 (“1Q FY2007"). The Company’s 2007 fiscal year ends on March 31, 2008.
1Q FY2007 Highlights -- Net revenues increased by 66.6% year-over-year to RMB151.5 million (US$19.9 million). -- Non-GAAP adjusted net income, as defined below, increased by 37.4% year-over-year to RMB68.7 million (US$9.0 million). The growth rate of non-GAAP adjusted net income was lower than that of net revenues primarily due to interest expense and amortization of convertible notes totalling RMB12.1 million (US$1.6 million). Net income increased by 12.6% year-over-year to RMB51.7 million (US$6.8 million). -- Non-GAAP adjusted diluted earnings per ADS*, as defined below, increased by 42.6% year-over-year to RMB2.61 (US$0.34). Diluted earnings per ADS increased by 16.7% year-over-year to RMB1.96 (US$0.26). * One American Depositary Share (“ADS”) = 10 ordinary shares
See “Non-GAAP Measure Disclosures” below, where the impact of certain items on reported results is discussed.
“We are pleased to see the momentum of this quarter’s business growth mainly driven by in-vitro diagnostic business. The revenue from IVD businesses has exceeded the revenue for HIFU business for the first time,” commented Mr. Xiaodong Wu, Chairman and CEO of the Company. “Going forward, we expect the seasonality of our HIFU business to have less impact on our results of operations and we will continue to benefit from the recurring nature of our IVD businesses including our ECLIA reagent business and our FISH probe business. We have successfully launched our FISH products and received very positive responses from many leading hospitals in the PRC. We believe our FISH business, in addition to our ECLIA business will become another major driver for our future growth.”
1Q FY2007 Financial Results
The Company reported net revenues of RMB151.5 million (US$19.9 million) for 1Q FY2007, representing a 66.6% increase from the corresponding period of FY2006.
The Company’s revenues are currently generated from three product lines, ECLIA diagnostic systems, FISH diagnostic systems and HIFU tumor therapy systems. ECLIA system sales include the sales of ECLIA analyzers and reagent kits. FISH system sales include the sales of FISH equipment and probes.
ECLIA system sales for 1Q FY2007 were RMB79.1 million (US$10.4 million), representing an 84.7% increase from the corresponding period of FY2006. The strong year-over-year growth in the ECLIA system sales reflected the increasing utilization of ECLIA analyzers by hospitals which drove increasing demand for reagent kits.
FISH system sales for 1Q FY2007 were RMB14.4 million (US$1.9 million) upon the launch of our FISH systems in this quarter. The sales represented only sales of equipment where sales of probes are expected in September quarter.
HIFU tumor therapy system sales for 1Q FY2007 were RMB58.0 million (US$7.6 million), representing a 20.5% increase from the corresponding period of FY2006. The year-over-year growth in this sector was driven primarily by increases in unit sales and selling price. Due to seasonality, first fiscal quarter is typically the weakest quarter for HIFU sales in a fiscal year.
Gross margin decreased to 62.0% for 1Q FY2007 as compared to 70.7% for the corresponding period of FY2006. The decrease in gross margin was due to the amortization of FISH intangible assets of RMB11.9 million (US$1.6 million) and FISH equipment sales which generated lower gross margin. The Company expects future FISH probe sales will generate recurring revenue and higher gross margin. The sales of FISH equipment is expected to drive up the use of FISH probes by hospitals. Excluding the impact of FISH amortization, gross margin would be 69.9%.
Research and development expenses were RMB9.8 million (US$1.3 million) for 1Q FY2007, representing a 66.8% year-over-year increase. The increase was due to expenses associated with the HIFU study organized by the Ministry of Health in the PRC, collaboration with research institutions and new product development.
Sales and marketing expenses were RMB5.8 million (US$0.8 million) for 1Q FY2007, representing a 38.3% year-over-year increase. The increase was primarily due to greater participation at exhibitions and more promotional events organized by the Company.
General and administrative expenses were RMB13.9 million (US$1.8 million) for 1Q FY2007, representing a 21.0% year-over-year increase. The increase was primarily due to increase in headcounts for expansion and stock compensation expense arising from recent stock grant in June 2007.
Interest income was RMB8.7 million (US$1.1 million) for 1Q FY2007, representing a 12.3% increase from the corresponding period of FY2006. The increase was primarily due to interest income generated from the net proceeds received from the issuance of convertible notes in November 2006.
Interest expense of convertible notes was RMB10.1 million (US$1.3 million) for 1Q FY2007 primarily due to interest incurred by the convertible notes issued in November 2006. The notes bear interest at 3.5% per annum.
Other interest expense of RMB1.6 million (US$0.2 million) for 1Q FY2007 was primarily due to notional interest in connection with the present value discounting of long term other payable of US$10 million for the final payment of FISH acquisition due in February 2009.
Amortization of convertible notes issuance cost of RMB2.0 million (US$0.3 million) for 1Q FY2007 was due to the US$150 million convertible notes issued in November 2006. The issuance cost is amortized over the term of the convertible notes which is five years.
Income tax expense was RMB7.9 million (US$1.0 million) for 1Q FY2007. One of the Company’s PRC subsidiaries is entitled to an income tax concession at a rate of 10% which will expire in December 2007. The effective tax rate for 1Q FY2007 was 13.3%.
On March 16, 2007, the 10th People’s Congress of China passed the China Unified Corporate Income Tax Law (the “New Law”), which will become effective on January 1, 2008. The New Law established a single unified 25% income tax rate for most companies with some preferential income tax rates including 15% income tax rate to be applicable to qualified hi-tech enterprises. The related detailed implementation rules and regulations (the “IRRs”) on the definition of various terms and the interpretation and application of the provisions of the New Law are expected to be promulgated by the State Council within 2007. The Company currently believes that the IRRs will not impact its qualification as a hi-tech enterprise, and as such, believes the current tax rate of 15% will continue to apply. In the event the promulgation of the new IRRs results in a change such that the Company will no longer qualify as a hi-tech enterprise, it will be required to pay income tax in accordance with the IRRs starting on January 1, 2008.
Net income was RMB51.7 million (US$6.8 million) for 1Q FY2007, representing a 12.6% increase from the corresponding period of FY2006.
Adjusted net income excluding stock compensation expense and amortization of acquired intangible assets (non-GAAP) was RMB68.7 million (US$9.0 million) for 1Q FY2007, representing a 37.4% increase from the corresponding period of FY2006. The lower growth rate compared to net revenues was primarily due to convertible note expenses of RMB12.1 million (US$1.6 million).
Stock compensation expense for 1Q FY2007 was RMB1.4 million (US$0.2 million) which was allocated to research and development expenses (RMB0.1 million) and general and administrative expenses (RMB1.3 million).
Amortization of acquired intangible assets for 1Q FY2007 was RMB15.6 million (US$2.1 million) which was allocated to cost of revenues.
As of June 30, 2007, the Company’s cash balance was RMB1.1 billion (US$150.5 million). Net operating cash flow for 1Q FY2007 was RMB73.3 million (US$9.6 million).
As of June 30, 2007, the Company’s accounts receivable was RMB215.3 million (US$28.3 million), representing an increase of 6.7% from the balance at March 31, 2007. The accounts receivable turnover days improved to 129 days from 135 days in previous quarter.
For the convenience of readers, certain RMB amounts have been translated into U.S. dollars at the rate of RMB7.612 to US$1.00, the noon buying rate in New York City for cable transfers of RMB per U.S. dollar as certified for customs purposes by the Federal Reserve Bank of New York, as of Friday, June 29, 2007.
Appointment and Resignation of Director
The Company announced that it has accepted Dr. Ruyu Du’s resignation as a member of the Board of Directors, including his position as a member of the nomination committee of the Company, effective September 30, 2007. Dr. Du has been a member of the Board of Directors since June 2005. He got a serious illness recently and is receiving continuous treatment. Mr. Xiaodong Wu, the Company’s Chairman and CEO, stated, “We express our sincere gratitude to the contribution that Dr. Du has made to the Company and wish him to recover from the illness.”
The Board of Directors has appointed Dr. Yuedong Li to the Board effective October 1, 2007. Dr. Li is currently the Chief Secretary of the China Hospital Association and the Deputy Director of Center of Organ Transplant at Beijing University. Dr. Li also holds various positions in a number of medical associations. He has over 30 years of experience in medical profession, clinical research and management of a number of healthcare organizations in the PRC. Mr. Wu stated, “We welcome Dr. Li to join our board. Dr. Li is an outstanding surgeon and a successful leader in healthcare organizations. His expertise will be invaluable to the rapid development of the Company.”
Outlook for FY2007
The Company is reassessing the current targets for FY2007 based on better than expected ECLIA reagent business and smooth progress of FISH business. The current targeted net revenues for FY2007 range from RMB830 million to RMB870 million. The current targeted adjusted net income excluding stock compensation expense and amortization of acquired intangible assets (non-GAAP) for FY2007 ranges from RMB390 million to RMB410 million. The current targeted adjusted diluted earnings per ADS excluding stock compensation expense and amortization of acquired intangible assets (non-GAAP) for FY2007 ranges from RMB14.15 to RMB14.80 assuming a diluted number of ADS of 31,000,000 and excluding interest for convertible notes and amortization of convertible notes issuance cost.
These targets are based on the Company’s current views on the operating and market conditions which are subject to change.
The assessment and revision on these targets will be completed when the Company reports its 2Q FY2007 financial results in November 2007.
Non-GAAP Measure Disclosures
To supplement its consolidated financial statements presented in accordance with United States Generally Accepted Accounting Principles (“GAAP”), the Company uses non-GAAP measures of adjusted net income and adjusted earnings per share, which are adjusted from results based on GAAP to exclude the impact of stock compensation expense and amortization of acquired intangible assets. Non-GAAP financial measures are used by the Company in their financial and operating decision-making because management believes they reflect the Company’s ongoing business in a manner that allows meaningful period-to-period comparison. The Company’s management believes that these non- GAAP financial measures provide useful information to investors and others in understanding and evaluating the Company’s current operating performance and future prospects in the same manner as management does, if they so choose. The Company’s management also believes the non-GAAP financial measures are useful for itself and investors because it makes more meaningful comparisons of the Company’s current results of operations to those of prior periods.
The Company’s management believes excluding the non-cash stock compensation expense from its non-GAAP financial measures is useful for itself and investors as such expense will not result in future cash payment and is otherwise unrelated to the Company’s core operating results.
The Company’s management believes excluding the non-cash amortization expense of acquired intangible assets resulting from acquisitions from its non-GAAP financial measures is useful for itself and investors because they enable a more meaningful comparison of the Company’s performance between reporting periods. In addition, such amortization will not result in cash settlement in the future.
The presentation of this additional financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. For a reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measure, please see the financial statements included with this press release.
Conference Call
The Company’s management team will host a conference call at 8:00 a.m. Eastern Time on August 28, 2007 (or 8:00 p.m. Beijing/Hong Kong time on August 28, 2007) to discuss the results following this earnings announcement.
The dial-in details for the live conference call are as follows: U.S. Toll Free Number 1-866-800-8652 International dial-in number 1-617-614-2705 Passcode CMEDCALL.
A live webcast of the conference call will be available on http://ir.chinameditech.com .
A replay of this webcast will be available for one month on this website.
A telephone replay of the call will be available after the conclusion of the conference call through 10:00 a.m. Eastern Time on August 29, 2007.
The dial-in details for the replay are as follows: U.S. Toll Free Number 1-888-286-8010 International dial in numbers 1-617-801-6888 Passcode 60687674
About China Medical Technologies
China Medical Technologies is a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostics products using Enhanced Chemiluminescence (ECLIA) technology and Fluorescent in situ Hybridization (FISH) technology, to detect and monitor various diseases and disorders, and system using High Intensity Focused Ultrasound (HIFU) for the treatment of solid cancers and benign tumors. For more information, please visit http://www.chinameditech.com .
Safe Harbor Statement
This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Among other things, the quotations from management in this press release, the Company’s strategic operational plans, as well as outlook for FY2007, contain forward-looking statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in the Company’s filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.
China Medical Technologies, Inc. Unaudited Condensed Consolidated Balance Sheets As of March 31, 2007 June 30, 2007 RMB RMB US$ (in thousands) Assets Current assets Cash and cash equivalents 1,173,640 1,145,271 150,456 Trade accounts receivable 201,778 215,335 28,289 Prepayments and other receivables 41,484 45,568 5,986 Inventories 27,991 31,902 4,191 Total current assets 1,444,893 1,438,076 188,922 Property, plant and equipment, net 135,791 147,075 19,321 Goodwill and other intangible assets, net (1) 1,355,735 1,323,732 173,901 Lease prepayments, net 7,620 7,573 995 Deferred income taxes 542 294 39 Convertible notes issuance costs 38,020 35,447 4,657 Total assets 2,982,601 2,952,197 387,835 Liabilities Current liabilities Trade accounts payable 47,847 55,499 7,291 Accrued liabilities and other payables 285,561 215,076 28,254 Income tax payable 38,467 39,252 5,157 Dividend payable -- 83,306 10,944 Total current liabilities 371,875 393,133 51,646 Convertible notes 1,158,480 1,141,800 150,000 Other payable - long term (1) 67,206 67,794 8,906 Deferred income taxes (1) 99,302 97,872 12,858 Total liabilities 1,696,863 1,700,599 223,410 Shareholders’ equity Share capital 225,125 225,125 29,575 Ordinary shares US$0.1 par value: 500,000,000 authorized; 273,600,001 issued and fully paid as of March 31 2007 and June 30, 2007 Additional paid-in capital 504,795 506,174 66,497 General reserve fund 36,147 36,147 4,749 Accumulated other comprehensive loss - cumulative translation adjustments (1) (21,336) (25,240) (3,316) Retained earnings 541,007 509,392 66,920 Total shareholders’ equity 1,285,738 1,251,598 164,425 Total liabilities and shareholders’ equity 2,982,601 2,952,197 387,835 Note: (1) The Company has revised preliminary purchase price allocation in connection with FISH acquisition based on revised internal valuation. The final purchase price allocation will be determined when the valuation by independent valuers is complete. China Medical Technologies, Inc. Unaudited Condensed Consolidated Statements of Income For the Three Months Ended June 30, March 31, 2006 2007 June 30, 2007 RMB RMB RMB US$ (in thousands except for per ADS information) Revenues, net (1) 90,948 163,103 151,490 19,901 Cost of revenues (26,617) (43,766) (57,496) (7,553) Gross profit 64,331 119,337 93,994 12,348 Operating expenses: Research and development (5,861) (7,960) (9,779) (1,285) Sales and marketing (4,161) (5,395) (5,755) (756) General and Administrative (11,528) (18,259) (13,946) (1,832) Total operating expenses (21,550) (31,614) (29,480) (3,873) Operating income 42,781 87,723 64,514 8,475 Other income -- 2,300 100 13 Interest income 7,743 15,143 8,694 1,142 Interest expense- convertible notes -- (10,183) (10,078) (1,324) Interest expense- other -- -- (1,569) (206) Amortization of convertible notes issuance cost -- (2,064) (2,043) (268) Income before tax 50,524 92,919 59,618 7,832 Income tax expense (4,606) (9,194) (7,927) (1,041) Net income 45,918 83,725 51,691 6,791 Earnings per ADS - basic 1.68 3.20 1.97 0.26 - diluted (2) 1.68 3.11 1.96 0.26 Weighted average number of ADS - basic 27,360,000 26,196,308 26,196,308 26,196,308 - diluted(2) 27,385,701 30,882,901 26,317,214 26,317,214 Notes: (1) Revenues, net - ECLIA 42,810 65,879 79,051 10,385 - FISH -- -- 14,442 1,897 - HIFU 48,138 97,224 57,997 7,619 90,948 163,103 151,490 19,901 (2) In computing diluted EPS for the three months ended March 31, 2007, interest expense and amortization in connection with convertible notes were added back to net income before dividing by the diluted number of ADS because potential shares from the conversion of convertible notes were included. For the three months ended June 30, 2007, the total number of potential shares to be converted pursuant to the conversion of convertible notes was not included in the computation of diluted EPS because to do so would have been anti-dilutive. China Medical Technologies, Inc. Reconciliations of Non-GAAP Adjusted Net Income to GAAP Net Income For the Three Months Ended June 30, March 31, 2006 2007 June 30, 2007 RMB RMB RMB US$ (in thousands except for per ADS information) GAAP net income 45,918 83,725 51,691 6,791 Adjustments: Stock compensation expense 321 311 1,379 181 Amortization of acquired intangible assets 3,729 7,747 15,607 2,050 Non-GAAP adjusted net income 49,968 91,783 68,677 9,022 GAAP earnings per ADS - basic 1.68 3.20 1.97 0.26 - diluted (1) 1.68 3.11 1.96 0.26 Non-GAAP adjusted earnings per ADS 1.83 3.50 2.62 0.34 - basic - diluted (1) 1.83 3.37 2.61 0.34 Weighted average number Of ADS - basic 27,360,000 26,196,308 26,196,308 26,196,308 - diluted (1) 27,385,701 30,882,901 26,317,214 26,317,214 Note: (1) In computing diluted GAAP and non-GAAP EPS for the three months ended March 31, 2007, interest expense and amortization in connection with convertible notes were added back to net income before dividing by the diluted number of ADS because potential shares from the conversion of convertible notes were included. For the three months ended June 30, 2007, the total number of potential shares to be converted pursuant to the conversion of convertible notes was not included in the computation of diluted EPS because to do so would have been anti- dilutive. For more information, please contact: China Medical Technologies, Inc. Winnie Fan Tel: +86-10-6530-8833 Email: IR@chinameditech.com
China Medical Technologies, Inc.
CONTACT: Winnie Fan of China Medical Technologies, Inc., +86-10-6530-8833,or IR@chinameditech.com
Web site: http://www.chinameditech.com/
